nafamostat has been researched along with Disease Exacerbation in 6 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with previously untreated pancreatic cancer received gemcitabine (1 000 mg/m(2) i." | 2.74 | A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. ( Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K, 2009) |
| "Bone metastases from gastric cancer (GC) are considered a relatively uncommon finding; however, they are related to poorer prognosis." | 2.52 | Targeting mast cells in gastric cancer with special reference to bone metastases. ( Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G, 2015) |
| "Since hypercortisolism due to active Cushing's disease may worsen a COVID-19 infection, multi-disciplinary management that includes appropriate and prompt treatment strategies is mandatory in such cases." | 1.62 | Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia. ( Atsumi, T; Cho, KY; Inoshita, N; Kamada, K; Kameda, H; Kenmotsu, Y; Konno, S; Miyoshi, H; Nakakubo, S; Nakamura, A; Nakamura, J; Nomoto, H; Sawamura, Y; Shimatsu, A; Sugino, H; Suzuki, M; Takahashi, Y; Yamashita, Y; Yuno, A, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Damalanka, VC | 1 |
| Voss, JJLP | 1 |
| Mahoney, MW | 1 |
| Primeau, T | 1 |
| Li, S | 1 |
| Klampfer, L | 1 |
| Janetka, JW | 1 |
| Ikeda, M | 1 |
| Okugawa, S | 1 |
| Kashiwabara, K | 1 |
| Moritoyo, T | 1 |
| Kanno, Y | 1 |
| Jubishi, D | 1 |
| Hashimoto, H | 1 |
| Okamoto, K | 1 |
| Tsushima, K | 1 |
| Uchida, Y | 1 |
| Mitsumura, T | 1 |
| Igari, H | 1 |
| Tsutsumi, T | 1 |
| Araoka, H | 1 |
| Yatera, K | 1 |
| Yamamoto, Y | 1 |
| Nakamura, Y | 1 |
| Otani, A | 1 |
| Yamashita, M | 1 |
| Wakimoto, Y | 1 |
| Shinohara, T | 1 |
| Adachi-Katayama, M | 1 |
| Oyabu, T | 1 |
| Kanematsu, A | 1 |
| Harada, S | 1 |
| Takeshita, Y | 1 |
| Nakano, Y | 1 |
| Miyazaki, Y | 1 |
| Sakao, S | 1 |
| Saito, M | 1 |
| Ogura, S | 1 |
| Yamasaki, K | 1 |
| Kawasuji, H | 1 |
| Hataji, O | 1 |
| Inoue, JI | 1 |
| Seto, Y | 1 |
| Moriya, K | 1 |
| Sagawa, T | 1 |
| Inoue, KI | 1 |
| Takano, H | 1 |
| Yuno, A | 1 |
| Kenmotsu, Y | 1 |
| Takahashi, Y | 1 |
| Nomoto, H | 1 |
| Kameda, H | 1 |
| Cho, KY | 1 |
| Nakamura, A | 1 |
| Yamashita, Y | 1 |
| Nakamura, J | 1 |
| Nakakubo, S | 1 |
| Kamada, K | 1 |
| Suzuki, M | 1 |
| Sugino, H | 1 |
| Inoshita, N | 1 |
| Konno, S | 1 |
| Miyoshi, H | 1 |
| Atsumi, T | 1 |
| Sawamura, Y | 1 |
| Shimatsu, A | 1 |
| Leporini, C | 1 |
| Ammendola, M | 1 |
| Marech, I | 1 |
| Sammarco, G | 1 |
| Sacco, R | 1 |
| Gadaleta, CD | 1 |
| Oakley, C | 1 |
| Russo, E | 1 |
| De Sarro, G | 1 |
| Ranieri, G | 1 |
| Uwagawa, T | 1 |
| Misawa, T | 1 |
| Sakamoto, T | 1 |
| Ito, R | 1 |
| Gocho, T | 1 |
| Shiba, H | 1 |
| Wakiyama, S | 1 |
| Hirohara, S | 1 |
| Sadaoka, S | 1 |
| Yanaga, K | 1 |
1 review available for nafamostat and Disease Exacerbation
| Article | Year |
|---|---|
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; | 2015 |
2 trials available for nafamostat and Disease Exacerbation
| Article | Year |
|---|---|
Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia.
Topics: Antiviral Agents; COVID-19; Disease Progression; Humans; SARS-CoV-2; Single-Blind Method; Treatment | 2023 |
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzam | 2009 |
3 other studies available for nafamostat and Disease Exacerbation
| Article | Year |
|---|---|
Macrocyclic Inhibitors of HGF-Activating Serine Proteases Overcome Resistance to Receptor Tyrosine Kinase Inhibitors and Block Lung Cancer Progression.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Discovery; Hepatocyte Growth Fact | 2021 |
Preventing the clinical manifestations and disease progression of coronavirus disease using clinically proven protease inhibitors.
Topics: Amides; Benzamidines; Betacoronavirus; Coronavirus; Coronavirus Infections; COVID-19; Critical Illne | 2020 |
Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Amides; Benzamidines; Combined Modality Therapy; C | 2021 |